Blood cells offer new way to stop corneal damage
News
Blood cells offer new way to stop corneal damage
In a world first, scientists at CERA have used tiny particles derived from blood to provide first-line treatment for corneal injuries.
Scientists at CERA have used tiny particles extracted from blood to deliver medicine to a cornea, opening the door for more effective management of corneal injuries.
The research – which is the first time this technique has been used in a model of the eye – was led by Associate Professor Guei-Sheung (Rick) Liu and published in the journal Biomaterials.
“We’re taking advantage of this natural system in the body to load in a drug to help heal damage from kinds of corneal injuries,” he says.
Corneal injuries caused by events like trauma, chemical spills or burns require urgent treatment to save a person’s sight or limit damage so a corneal transplant can be successful.
Anti-inflammatory drugs, such as steroids, are a critical first step to help reduce corneal damage and are typically delivered via an eye drop.
However, Associate Professor Liu explains that conventional eye drops are not an ideal delivery system.
“When you use an eye drop less than five percent of the medicine actually stays in the eye – the rest runs out – so it is not as effective as it could be,” he says.
A more effective and efficient way of delivering the treatment could lead to more people recovering their sight, particularly in developing countries where corneal injuries are much more common.
Associate Professor Liu and his team implemented a new method of delivering treatment using tiny particles taken from a person’s blood.

Blood extraction
Platelets are blood cells that play a critical role in healing wounds – they clump together to heal cuts and prevent bleeding.
When healing wounds platelets release platelet-derived extracellular vesicles (PEVs) – tiny particles that help with this process.
Associate Professor Liu and his team took these PEVs and loaded them with an anti-inflammatory drug – successfully using them to reduce inflammation in the injured cornea.
“PEVs offer several important advantages over existing drug delivery methods,” says Associate Professor Liu.
“They are very small particles that are easily absorbed into the cornea, they naturally occur in the body so won’t trigger the immune system, and because they come from blood they are very easy to source.
“We also found that PEVs also help reduce inflammation and promote tissue repair a little just on their own, so they are beneficial in many ways.”
Better treatments
Associate Professor Liu says that while corneal injuries are a start, the team’s future research will look at more treatments that could potentially be delivered.
This could include emerging treatments for other eye conditions like age-related macular degeneration and glaucoma
He undertook this work in collaboration with a team from Taipei Medical University led by Professor Ching-Li Tseng, who will be coming to CERA to work with him for the next two years to continue the work.
“The team is made up of biomaterial experts and bioengineers who will contribute a lot to what CERA can do in this area,” he says.
Read the research
Guei-Sheung Liu, Huai-An Chen, Che-Yi Chang, Yin-Ju Chen, Yu-Yi Wu, Ariel Widhibrata, Ya-Han Yang, Erh-Hsuan Hsieh, Liling Delila, I-Chan Lin, Thierry Burnouf, Ching-Li Tseng, Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization, Biomaterials Volume 319, 2025, https://doi.org/10.1016/j.biomaterials.2025.123205